ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key Stats

• Today's Range: $0.59 to $0.73
• 50-Day Range: $0.57 to $1.08
• 52-Week Range: $0.46 to $2.59
• Volume: 1.54 million shs
• Average Volume: 700,626 shs
• Market Capitalization: $201.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Hold

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 36% of companies evaluated by MarketBeat, and ranked 2014th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

ProKidney has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

ProKidney has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProKidney are expected to grow in the coming year, from ($0.57) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProKidney is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProKidney is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.84% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 18.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently increased by 1.69%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.84% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 18.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently increased by 1.69%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.04

News Sentiment

ProKidney has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for ProKidney this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,175,419.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROK Stock Analysis - Frequently Asked Questions

How have PROK shares performed this year?

ProKidney's stock was trading at $1.69 at the start of the year. Since then, PROK shares have decreased by 59.2% and is now trading at $0.6890.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) issued its earnings results on Monday, May, 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProKidney own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.50
• High Stock Price Target: $6.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +408.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.19 million
• Net Margins: N/A
• Pretax Margin: -54,267.64%
• Return on Equity: N/A
• Return on Assets: -15.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.96
• Quick Ratio: 10.96

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 2,520.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.41) per share
• Price / Book: -0.20

Miscellaneous

• Outstanding Shares: 292,700,000
• Free Float: 171,258,000
• Market Cap: $201.67 million
• Optionable: Optionable
• Beta: 1.26